Synthetic methods for preparing deoxycholic acid and intermediates thereof are provided.

The present disclosure is generally directed to neuroactive enantiomeric 15-, 16- and 17-substituted steroids with additional optional substituents at carbons 3, 4, 6, 7, 10 and 13, and pharmaceutically acceptable salts thereof, for use as, for example, modulators for GABA type-A receptors. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.

The present disclosure is generally directed to neuroactive enantiomeric 15-, 16- and 17-substituted steroids with additional optional substituents at carbons 3, 4, 6, 7, 10 and 13, and pharmaceutically acceptable salts thereof, for use as, for example, modulators for GABA type-A receptors. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.

Disclosed are compounds of the formula: ##STR00001##
wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently hydrogen, C.sub.1-C.sub.6 alkyl, halo, a sulfate, a glucuronide, OH, a bulky group, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, N(CH.sub.2).sub.n; a phosphate group, and a phosphinate group; R.sub.9 is hydrogen, halogen or alkyl; R.sub.11 is selected from the group consisting of H, C.sub.1-C.sub.6 alkyl, halogen, a sulfate, a glucoronide, SO.sub.2NH.sub.2, COOH, CN, CH.sub.2CN, NHCN, CHO, CHOCH.sub.3, COO salt, OSO.sub.2alkyl, NH.sub.2, and NHCO(CH.sub.2).sub.n; R.sub.12 is selected from the group consisting of H, a C.sub.1-C.sub.6 alkyl, a sulfate, a glucoronide, a bulky group, aryl, cycloalkyl, heteroaryl and heterocycloalkyl; X is selected from the group consisting of C.sub.1-C.sub.12 alkyl, C.sub.2-C.sub.12 alkenyl, C.sub.2-C.sub.12 alkynyl, halogen, a glucoronide, NH.sub.2, SO.sub.2NH.sub.2, COOH, CN, CH.sub.2CN, NHCN, CHO, COOsalt, OSO.sub.2alkyl, SH, SCH.sub.3, CH[(CH.sub.2).sub.nCH.sub.3]COOCH.sub.3, (CH.sub.2).sub.mCOOCH.sub.3, (CH.sub.2).sub.mOCH.sub.3, (CH.sub.2).sub.mO(CH.sub.2).sub.nCH.sub.3, (CH.sub.2).sub.mSCH.sub.3, (CH.sub.2).sub.mS(CH.sub.2).sub.nCH.sub.3, (CH.sub.2).sub.mNH(CH.sub.2).sub.nCH.sub.3, C.sub.2-C.sub.8 alkenyl-O(CH.sub.2).sub.nCH.sub.3, C.sub.2-C.sub.8 alkenyl-S(CH.sub.2).sub.nCH.sub.3, C.sub.2-C.sub.8 alkenyl-N(CH.sub.2).sub.nCH.sub.3, C.sub.2-C.sub.8 alkynyl-O(CH.sub.2).sub.nCH.sub.3, C.sub.2-C.sub.8 alkynyl-S(CH.sub.2).sub.nCH.sub.3, C.sub.2-C.sub.8 alkynyl-N(CH.sub.2).sub.nCH.sub.3, (CH.sub.2).sub.mOH, (CH.sub.2).sub.mONH.sub.2, (CH.sub.2).sub.mSNH.sub.2, NH(CH.sub.2).sub.mCH.sub.3, NH(CH.sub.2).sub.mOCH.sub.3, NH(CH.sub.2).sub.mCHOHCOOH, N(CH.sub.3).sub.2, (CH.sub.2).sub.m(NH)CH.sub.2OH, NHCOOH, (CH.sub.2).sub.mNHCOOH, NO.sub.2, SCN, SO.sub.2alkyl, B(OH).sub.2, (CH.sub.2).sub.mN(CH.sub.3)SO.sub.2NH.sub.3, (CH.sub.2).sub.mNHSO.sub.2NH.sub.2, NHC(S) CH.sub.3, and NHNH.sub.2; and Y is selected from hydrogen, O, OCO(R.sub.6) and OH; wherein m is an integer between 0-20, n is an integer between 0-8, the symbol represents either a single or a double bond capable of forming a keto group at position 3 or 17; and the symbol represents any type of bond regardless of the stereochemistry; and the respective enantiomers, othe

The present invention discloses method for preparing deoxycholic acid (DCA) or an ester thereof or a pharmaceutically acceptable salt thereof. Said compounds may be applied to remove a fat deposition.

Compounds are provided according to Formula (I):

##STR00001##

and pharmaceutically acceptable salts thereof, wherein Z is a group of the formula (i), (ii), (iii), (iv), or (v):

##STR00002##

and wherein L.sup.1, L.sup.2, L.sup.3, X.sup.1, X.sup.2, Y, R.sup.Z4, R.sup.Z5, R.sup.Z6, n, R.sup.1, R.sup.2, R.sup.3a, R.sup.3b, R.sup.4a, R.sup.4b, R.sup.6a, R.sup.6b, R.sup.7a, R.sup.7b, R.sup.11a, R.sup.11b, R.sup.14, R.sup.17, R.sup.19, R.sup.20, R.sup.23a, R.sup.23b, and R.sup.24 are as defined herein, and pharmaceutical compositions thereof. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions in mammals.

Compounds are provided according to Formula (I):

##STR00001##

and pharmaceutically acceptable salts thereof, wherein Z is a group of the formula (i), (ii), (iii), (iv), or (v):

##STR00002##

and wherein L.sup.1, L.sup.2, L.sup.3, X.sup.1, X.sup.2, Y, R.sup.Z4, R.sup.Z5, R.sup.Z6, n, R.sup.1, R.sup.2, R.sup.3a, R.sup.3b, R.sup.4a, R.sup.4b, R.sup.6a, R.sup.6b, R.sup.7a, R.sup.7b, R.sup.11a, R.sup.11b, R.sup.14, R.sup.17, R.sup.19, R.sup.20, R.sup.23a, R.sup.23b, and R.sup.24 are as defined herein, and pharmaceutical compositions thereof. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions in mammals.

The present disclosure relates to stereodefined polycyclic (e.g., tetracyclic) compounds that contain quaternary centers at one or multiple ring fusions, synthetic methods for preparing such compounds, and methods of using such compounds to treat a disease, such as a brain tumor and, particularly, a glioma.

Novel antimicrobial compounds against drug targets such as Eskape pathogens, Leishmania donovani, Mycobacterium tuberculosis, Clostridium difficile, Naegleria fowleri, and cancer are presented herein.

Novel antimicrobial compounds against drug targets such as Eskape pathogens, Leishmania donovani, Mycobacterium tuberculosis, Clostridium difficile, Naegleria fowleri, and cancer are presented herein.